

THE USE OF '*GARCINIA KOLA*' IN THE TREATMENT OF ORAL CANDIDA INFECTION IN HIV PATIENTS

Abah A A¹, Agbelusi G A², Odukoya O A³, Ayanbadejo P O², Adefule-Ositelu A O⁴, Adebisi K E¹

¹Department of Oral Pathology/Oral Medicine, Lagos State University College of Medicine, ²Department of Preventive Dentistry, Faculty of Dentistry, College of Medicine, University of Lagos, ³Department of Pharmacognosy, Faculty of Pharmacy, University of Lagos, ⁴Department of Ophthalmology College of Medicine, University of Lagos

ABSTRACT

BACKGROUND: The antifungal effect of chlorhexidine has been demonstrated for the treatment of oral candidiasis in Human Immunodeficiency virus positive patients. However, it is associated with teeth and mucosal staining, bitter taste and it is not readily available in an average Nigerian pharmacy shop. *Garcinia kola* is affordable, widely available antifungal agent with no reported side effects. This study aims to determine the effect of *Garcinia kola* extract on oral *Candida* infection in HIV patients; to compare its efficacy with chlorhexidine mouthwash and to assess the side effects of *Garcinia kola*.

MATERIALS AND METHODS: A double blinded clinical trial was carried out on newly diagnosed HIV patients with clinically diagnosed *Candida* infection at Aids Preventive Initiative of Nigeria clinic of Lagos University Teaching Hospital, Nigeria. They were also screened for other medical conditions. *Garcinia kola* extract and chlorhexidine mouthwash were administered for 3 weeks to the patients randomly selected into the two treatment groups of 33 patients each.

RESULTS: Sixty one patients completed the study, with 33 patients on G. kola and 28 patients on chlorhexidine. Oral Candidiasis was cleared with *Garcinia kola* in 27 (81.8%) patients, while 20(71.4%) patients had it cleared with chlorhexidine at the end of the 3rd week. There was no statistical significant difference between patients' response to *Garcinia kola* and chlorhexidine.

CONCLUSION: This study has shown that *Garcinia kola* is effective against candida infection. For cost-effective treatment of oral candida infection in resource limited countries, *Garcinia kola* may be considered a preferred alternative to chlorhexidine.

Keywords: Candida infection, HIV patient, *Garcinia kola*, Chlorhexidine.

Address for correspondence:

Abah A. A.
Department of Oral
Pathology/Oral Medicine,
Lagos State University
College of Medicine
+2348023390024
debowun@gmail.com

INTRODUCTION

Candida infections, otherwise known as candidiasis, moniliasis, commonly occur in patients who are immunocompromised in conditions such as in leukemia, diabetes and Human Immunodeficiency Virus or Acquired immunodeficiency syndrome (HIV/AIDS). However, without treatment in HIV/AIDS, oral candidiasis may spread to the oesophagus causing invasive oesophageal candidiasis and disseminated candidiasis, which is categorized as an AIDS defining illness. Human Immunodeficiency virus (HIV) infection is a global pandemic and a critical public health problem. HIV is a retrovirus that belongs to the family of lentiviruses. It is a highly variable virus which mutates very readily within the body of an infected person. There are two types of HIV patients: HIV-1 and HIV-2. HIV/AIDS patients which are prone to candida infection and other opportunistic infections.

Oral Candida infection can be treated with antifungal drugs such as nystatin, miconazole, fluconazole, voriconazole, and caspofungin. Many of them are associated with side effects which include nausea, vomiting, diarrhoea, headache, hepatitis, dyspepsia, skin rashes, and fever. Drug resistance is also a common feature with them^{1,2,3} All these resulted in the drive for alternate medications. Alternate to the commonly used oral antifungal suspension is chlorhexidine. This is also known to have side effects which include staining of teeth and tongue and change in taste. These also discourage drug compliance, which prompted us to the quest for another alternative drug, *Garcinia kola*.

Garcinia kola (*G. Kola*) Heckel (family *Guttifera*) is known in commerce as 'bitter kola', 'false kola' or 'male kola'; it is also called 'akiilu' in Igbo, 'orogbo' in Yoruba, and 'namiji goro' in Hausa.^{4,5} *Garcinia kola*

is a medium-sized evergreen tree, mostly about 12m high but sometimes up to 28m in height, and 1 to 5m width.⁶ It is a food and of high socio-economic importance. Some proprietary dietary supplements containing *G. kola* extracts already exist in U.S.A. and some African markets.⁷ It is widely used in traditional medicine and with great promises for modern clinical uses. *Garcinia kola* has many chemical components, but (B-1a) (hydroxybiflavanonol) is the main component exhibiting significant ($p < 0.005$) bacteriocidal activity against Gram positive and Gram negative bacteria, and fungistatic against *Candida albican* and *Aspergillus flavus*. Ongoing researches have shown *G. kola* to have effect on some common microorganisms.⁸

Therefore, the objectives of the study were to determine the effect of *Garcinia kola* extract on oral *Candida* infection in HIV patients; to compare its efficacy with chlorhexidine mouthwash and to assess the side effects of *Garcinia kola*.

MATERIALS AND METHODS

A double blinded clinical trial was carried out on newly diagnosed HIV patients with clinically diagnosed *Candida* infection at Aids Preventive Initiative of Nigeria (APIN) clinic of Lagos University Teaching Hospital (LUTH), Lagos, Nigeria. Every consecutive HIV positive patient presenting with oral candidiasis were recruited among the patients seen in the APIN clinic, LUTH.

The patients were also screened for other medical conditions to rule out any other underlying medical problems. Written informed consent was obtained from all the patients before enrollment in the study. Ethical approval for the study was obtained from the Health Research and Ethics committee of Lagos University Teaching Hospital (LUTH).

The concentration of chlorhexidine used was 0.2%. A concentration of 30% (30g in 100ml) of *G.kola* was obtained by cold extraction process which was like ordinarily chewing the nut under hygienic condition. Preparation of the *G. kola* extract was performed using *G.kola* nuts of about 2000g by weight. The seed coats on the nuts were removed to expose the white inner parts, before the nuts were washed, cut into pieces and blended. The water extraction mixture obtained was poured into a beaker and allowed to stand on the bench for 15 hours.⁹ It was filtered and the extract (supernatant) was preserved in the refrigerator for the clinical trial.

The patients were randomly allocated by a trained assistant to two different treatment groups (*Garcinia kola* extract and Chlorhexidine). There were 33 patients in *Garcinia kola* group and 33 in chlorhexidine group. The mouth rinses were dispensed in identical containers, labeled A and B. The assistant thereafter dispensed the different mouthwashes to the patients according to the group they have been randomly assigned to. Each patients was told to use the mouthwash 3 times daily and 30minutes before using any fluoride containing toothpastes (this is to prevent inactivation of chlorhexidine). They were also told to swish the solution around the mouth and leave for 1min before spitting out.

At the end of the 3rd week, the treatment was stopped. The assistant kept a record of the treatment received by each patient. The investigator was not aware of the patients' treatment groups until after the final treatment outcome was determined. Administration of questionnaire and clinical examination were used to collect the patients' data.

The patients were reviewed weekly and the treatment outcome was recorded. All the patients had 3 recall visits. The clinical effectiveness of *Garcinia kola* extract and

chlorhexidine was determined using these criteria:

1. Totally cleared (the lesion completely cleared in the oral cavity)
2. Partially cleared (the lesion partially cleared in the oral mucosa)
3. Not cleared (the lesion remained the same).

During the period of this study, no observable side effect(s) of *G.kola* and chlorhexidine was noticed. The patients whose Candida infection did not clear at the end of the third week were placed on fluconazole.

RESULTS

A total of 66 patients were selected but 61 (92.4%) patients completed this study and were analyzed. There were 43(70.5%) females and 18 (29.5%) males, with female to male ratio of 2.4:1. Most of the patients were in the 30 to 39 years (37.7%) age group, with a mean age of 37.2 ± 11 years and a median age of 35 years (Table 1).

The pattern of distribution of the disease was: 28(45.9%) patients with erythematous candidiasis, 22 (36.1%) patients with pseudomembranous candidiasis, 6(9.8%) patients with angular cheilitis and 5(8.2%) patients combination of pseudomembranous and erythematous candidiasis. Erythematous candidiasis was the most common variant seen.

In the *G. kola* group with 33 patients who completed the study, 27 (81.8%) of the patients had their oral candidiasis completely cleared at the end of the 3rd week. The rate at which the lesion cleared was higher between week 2 and 3 than during the first week. In the chlorhexidine group with 28 patients, with a higher rate of

clearing between week 2 and 3 than during week 1, but at a consistently lower rate than with G. kola. At the end of the 3rd week, 20(71.4%) patients had their lesion completely cleared. Observation showed that more patients had their lesions cleared during the follow up period with G. kola than with chlorhexidine (Figure 1).


Table 1: Age distribution of patients

Age (year)	HIV positive (n = 61)	
	Frequency	Percent
< 20	3	4.9
20 -29	11	18.0
30 -39	23	37.7
40 -49	15	24.6
50 -59	7	11.5
≥ 60	2	3.3
Total	61	100

DISCUSSION

Previous study by Kantheti LP et al,¹⁰ reported female preponderance where the prevalence of *Candida* colonization was determined in HIV positive patients naive to highly active anti-retroviral therapy (HAART). Similarly, there was female predilection for HIV positive patients with oral candidiasis in this study. Furthermore, the infection has been reported to be more prevalent in individuals within the 30 to 39 years age group who are usually more sexually active.¹¹ This is consistent the findings in this study.

Figure 1: Proportion of HIV positive patients with no more sign of candidiasis



Erythematous candidiasis (45.9%) and pseudomembranous candidiasis (36.1%) were the most common types of candida infections in this study. Report by Bodhachari et al,¹² have shown that erythematous candidiasis is dominant in patients infected with HIV virus. This is contrary to the findings of Agbelusi et al.,¹³ Arotiba et al.,¹⁴ and Taiwo et al.,¹⁵ who observe pseudomembranous candidiasis to be the dominant variant. Vanderwaal et al.,¹⁶ also observed pseudomembranous candidiasis to be a dominant variant in AIDS patients.

In the HIV positive patients studied, the success rate of *Garcinia kola* was 81.8% while the success rate was 71.4% for chlorhexidine. Chlorhexidine has fungistatic and fungicidal action^{17,18, 19}. The antifungal effects which have been demonstrated both in vivo and in vitro include its effects on *Candida*.^{20,21,22} Chlorhexidine (0.2%) is widely prescribed due to its broad spectrum activity on bacteria and *C.albicans*.^{23,24} Studies have shown that exposure of *C.albicans* isolates or the buccal epithelial cells to 0.2% chlorhexidine gluconate profoundly suppressed the ability of

to adhere to buccal cells, both in healthy^{28,29} and diseased individuals.³² This evidence reveals it as an appropriate alternative to conventional antifungals in the management of oral candidiasis.^{31,32} Ellepola and Samaranayake³⁰ showed its importance as an adjunct in the treatment of *candidal* infection with conventional antifungal drug, which has a short duration of action (chlorhexidine has a long duration of action) supporting its use as an alternate oral antifungal therapy. However, this study also showed *Garcinia kola* to be more effective against *Candida* than Chlorhexidine.

Interest in plant extracts demonstrating antimicrobial and pharmacological ability is on the increase recently.^{28,29} Medicinal plants are important sources of new chemical substances with potential therapeutic benefits.³⁰ Phytochemicals derived from plants have shown great promise in the treatment of intractable infectious diseases including opportunistic AIDS infections. Plants containing *Garcinia* biflavonones have been found to be active against a wide variety of micro-organisms. *G. kola* has been shown to have anti-fungal effect from its crude extracts demonstrated by the study carried out at the Guinness Eye centre, LUTH, where fungal samples cultured from swabs obtained from conjunctiva discharges of the patients exhibited significant sensitivity and growth inhibition. These organisms were *Candida albicans*, *Bacillus subtilis*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Enterococcus faecalis*, *Escherichia coli*, and *Klebsiella pyocyanaceae* amongst others.³¹ Similar work done by Akerele et al.,⁹ also showed clinical significant inhibitory activities against these micro-organisms. It has also been shown reported by Sote and Wilson³² to be effective against *Fusobacterium nucleatum*, *Prevotella intermedia* and *Campylobacter* *gingivalis*.

Other in vitro studies carried out on *Garcinia kola* were control of trypanosome proliferation in mice,³³ fertility enhancer in cat fish,³⁴ reduction of intraocular pressure and miotic (as antiglaucoma),³⁵ thus further supporting the benefits of *Garcinia kola*. It was also used to reduce pain and sub-chondral pressure in knee osteo-arthritis in an in-vivo study.³⁶ In the present study, no observable side effect was noticed with *Garcinia kola*, similar to previous report by Dada and Ikuerowo.³⁷ Those whose candidal infection did not clear were given fluconazole at APIN clinic.

In conclusion, this study has shown that *Garcinia kola* is effective against candida infection. For cost-effective treatment of oral candida infection in resource limited countries, *Garcinia kola* may be considered a preferred alternative to chlorhexidine.

Recommendation: The effect of *Garcinia kola* on oral candida infection on HIV in this study is encouraging, though the lesion did not clear totally in some patients at the end of the 3rd week. Further studies may reveal better ways of utilizing *Garcinia kola* for a more effective treatment of oral candidiasis.

Conflict of interest: none declared

REFERENCES

1. Munoz P, Moreno S, Berenguer J, Bernaldo de Quiros JC, et. al. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1991; 151:1020-1021.
2. Ally R, Schurmann D, Kreisel W, Carosi G, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001; 33:1447-1454.

3. Maertens J, Raad I, Petrikos G, Boogaerts M, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563-1571.
4. Exomonu UG, El-Taalu AB, Anuka JA, Ndodo N D. Effects of ingestion of ethanol extracts of *Garcinia Kola* seed on erythrocytes in wistar rats. Nig J. Physio. Sci. 2005; 20 (1-2): 30-32.
5. Hong XL, Song FL. Activity of plant flavonoids against antibiotic-resistant bacteria. Phytother. Res. 2001;15: 39-43.
6. Adedeji OS, Farinu GO, Ameen SA, Olayemi TB. The effects of dietary bitter kola (*Garcinia kola*) inclusion on body weight, hematology and survival rate of pullet chicks. J. Anim. Vet. Adv. 2006; 5 (3): 184-187.
7. Meserole L. *Garcinia kola* in clinical therapeutics – present and potential indications as a tonic and therapeutic medicine. A colloquium on *Garcinia kola* presented in International conference on ethnomedicine and drug discovery. Maryland, USA. PL-2; Nov 3-5, 1999.
8. Mboto C I, Eja M E, Adegoke A A, Iwatt G D, et al. Phytochemical properties and antimicrobial activities of combined effect of extracts of the leaves of *Garcinia kola*, *Vernonia amygdalina* and honey on some medically important microorganisms. Afr. J. Microbio. Res. 2009; 3(9) 557-559.
9. Akerele J O, Osahon O M, Ebomoyi I, Israel O E, Osamuyi H U. Antimicrobial activity of the ethanol extract and fractions of the seed of *Garcinia kola* Heckel (Guttiferae). Afr J. Biotechnol. 2008; 7 (2):169-172.
10. Kantheti LP, Reddy B, Ravikumar S, Anuradha CH, et al. Isolation, identification and carriage of *Candida* species in PHLAs and their correlation with immunological status in cases with and without HAART. J Oral Maxillofac Pathol. 2012; 16: 38-44.
11. Mlay M, Bukari M. The prevalence of HIV among patients admitted with stroke at the Muhimbili National Hospital, Dar es Salaam, Tanzania. J. Health Res. 2010;12(2):1-12.
12. Bodhade AS, Ganvir SM, Hazarey VK. Oral manifestation of HIV infection and its correlation with CD4 count. J Oral Sci. 2001; 53 (2): 203-211.
13. Agbelusi GA, Sofola OO, Uti OG. Oral candidiasis in a group of HIV positive Nigerians. Afr. J. Oral Health. 2006; 2 (1): 57-62.
14. Arotiba JJ, Adebola RA, Iiyasu Babashani M, et al. Oral manifestation of HIV/AIDS in Nigerian patients seen in Kano. Nig J. Surg. Res. 2005; 7(1-2): 171-181.
15. Taiwo OO, Okeke EN, Otoh EC, Danfo IS. Prevalence of HIV-related oral lesions in Nigerian women. Niger J. Med. 2005; 14(3): 132-136.
16. Vander waal I, Schulten EA, Pindborg JJ. "Oral manifestation of AIDS: an overview". Internat Dent J. 1991; 41(1): 3-8.
17. Pizzo G, Guiliana G. Antifungal properties of chlorhexidine containing mouth rinse. An invitro study. Minerva Stomatol. 1998; 47(12): 665-671.
18. Joel BE. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in Leukemia and bone marrow transplantation. Oral Surg-Oral Med- Oral Pathol. 1992; 73(6): 682-689.
19. Arikan A, Kulak Y, Kadir T. Comparison of different treatment methods for localized and generalized simple denture stomatitis. Oral Rehab. 1995;22 (5); 365-369.
20. Ellepola ANB, Samaranayake L. Adjunctive use of chlorhexidine in oral candidiasis: a review. Oral Dis. 2001; 7 (1): 11-17.
21. Guiliana G, Pizzo G, Milli ME. In vitro antifungal properties of mouthrinse containing antimicrobial agents. J. Periodontol. 1997; 68:729-733.
22. Giuliana G, Pizzo G, Milici ME. In vitro activities of antimicrobial agents against *Candida* species. Oral Surg, Oral Med & Oral Radiol Endod. 1999; 87:44-48.
23. Salem A M, Adams D, Newman H. Antimicrobial properties of 2 aliphatic amines and chlorhexidine in-vitro and in saliva. J. Clin. Periodontol. 1987; 14: 44-48.

24. MacNeill S, Rindler E W. Effect of tetracycline hydrochloride and chlorhexidine gluconate on *C. albicans*. An invitro study. *J Clin Periodontol*. 1997; 24 (10): 753-760.
25. Gorman SP, McCafferty DF, Woolfon AD. A comparative study of the microbial adherence capacities of three antimicrobial agents. *J. Clin. Pharm. Ther.* 1987; 12: 393-399.
26. Togbi RS, Samaranayake LP, MacFarlane TW. In vitro susceptibility of *Candida* species to lysozyme. *Oral Microbiol Immunol*. 1988; 3:35-39.
27. Darwazeh AM, Lamsey PJ, MacFarlane TW. The effect of exposure to chlorhexidine gluconate in vitro and in vivo on invitro adhesion of *Candida albicans* to buccal epithelial cells from diabetic and non-diabetic subjects. *J.Oral Pathol Med*.1994; 23: 130-132.
28. Soforowa EA. The state of Medicinal plant research in Nigeria. *Niger. Soc. Pharmacognosy*.1986; 6: 54-96.
29. Nweze EL, Okafor JL, Njoku O. Antimicrobial activity of methanol extract of *Trune guineensis* (Schumm and thorn) and *Morinda icida* benth used in Nigerian Herbal Medicinal Practice. *J. Biol. Res. Biotechnol*.2004; 2(1): 39-46.
30. Shagal MH, Modibbo UV, Liman AB. Pharmacological justification for the ethnomedical use of *Datura Stramonium* stem bark extract in the treatment of diseases caused by some pathogenic bacteria. *Int Res Pharm Pharmacol*. 2012; 2(1): 16-19.
31. Adefule-Ositelu AO, Adefule AK, Dosa BO, Onyenefa P.C. Antifungal activities of *Garcinia kola* extracts on purulent human ocular discharges in Lagos University Teaching Hospital. *Nig. Qt. J. Hosp*. 2004; 14 (1): 112-114.
32. Sote EO, Wilson M. The in vitro antibacterial effects of extracts of Nigerian tooth cleaning sticks on periodontopathic bacteria. *Afr. Dent. J*.1999; 91: 15-19.
33. Akpantah AO, Oremosu AA, Noronha CC, Ekanem TB, et al. Effects of *Garcinia kola* seed extract on ovulation, oestrous cycle and foetal development in cyclic female Sprague-Dawley rats. *Nig J Physio Sci*.2005; 20 (1-2): 246-252.
34. Dada AA, Ajilore VO. Use of ethanol extracts of *Garcinia kola* as fertility enhancer in female catfish (*Clarias gariepinus*) broodstock. *Int. J. Fish. Aquac*.2009; 1 (1): 5010.
35. Adefule-Ositelu AO, Onakoya AO, Adefule AK, Dosa BOS. Comparative chromatographic analysis and pharmacodynamic activities of *Garcinia kola* extracts. *Nig. Qt. J. Hosp. Med*.2005; 15(1): 30-33.
36. Adegbehingbe OO, Adesanya SA, Idowu TO, Okimi O C,et al. Clinical effects of *Garcinia kola* in knee osteoarthritis. *J. Ortho Surg*.2008; 3:34.90.
37. Dada AA, Ikurowo M. Effects of ethanolic extracts of *Garcinia kola* seeds on growth and heamatology of catfish (*Clarias gariepinus*) broodstock. *Afri J. Agric. Res*.2009; 4(4): 344-347.